QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients’ vital signs and evaluate the effects of prescribed medicines and treatments on patients’ health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.’s products and services are designed to help physicians improve patient monitoring and medical care while also improving the revenues of their practice.
Company profile
Ticker
USAQ
Exchange
Website
CEO
Troy Grogan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
AMERICAN BIOGENETIC SCIENCES INC, USA EQUITIES CORP.
SEC CIK
Corporate docs
IRS number
112655906
USAQ stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
18 Apr 24
8-K
QHSLab Announces Impressive 2023 Fiscal Year Results with Growing Revenues, Improved Gross Margins, and Substantial Reduction in Net Loss
28 Mar 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Regulation FD Disclosure
30 Jan 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Regulation FD Disclosure
25 Oct 23
8-K
Regulation FD Disclosure
18 Oct 23
8-K
Entry into a Material Definitive Agreement
6 Oct 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
QHSLab, Inc. Reports First Quarter Financial Results
15 May 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 50.24 k | 50.24 k | 50.24 k | 50.24 k | 50.24 k | 50.24 k |
Cash burn (monthly) | 19.54 k | 15.64 k | 11.74 k | 28.12 k | (no burn) | 7.85 k |
Cash used (since last report) | 132.69 k | 106.24 k | 79.77 k | 191.01 k | n/a | 53.35 k |
Cash remaining | -82.45 k | -56.00 k | -29.53 k | -140.77 k | n/a | -3.11 k |
Runway (months of cash) | -4.2 | -3.6 | -2.5 | -5.0 | n/a | -0.4 |